gadopiclenol

Also Known As:

3,6,9,15-Tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetic acid, alpha, alpha', alpha''-tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-, gadolinium salt (1:1); Gadolinium 2,2',2''-(3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triyl)tris(5-((2,3-dihydroxypropyl)amino)-5-oxopentanoate)

Networked: 11 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Robert, Philippe: 5 articles (10/2022 - 01/2019)
2.	Corot, Claire: 4 articles (01/2022 - 01/2019)
3.	Factor, Cécile: 3 articles (10/2022 - 12/2021)
4.	Rasschaert, Marlène: 3 articles (10/2022 - 12/2021)
5.	Idée, Jean-Marc: 2 articles (01/2022 - 12/2021)
6.	Funke, Sabrina K I: 1 article (10/2022)
7.	Karst, Uwe: 1 article (10/2022)
8.	Lezius, Lena: 1 article (10/2022)
9.	Sperling, Michael: 1 article (10/2022)
10.	Catoen, Sarah: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "For both readers, 0.05 mmol/kg of gadopiclenol improved contrast enhancement, border delineation, and visualization of tumor morphology (scores > 3 compared with scores between 2 and 3 for the marketed GBCA). " 11/03/2023 - "Tumor detection was higher after gadopiclenol at the dose of 0.1 mmol/kg compared with 0.08 mmol/kg." 01/01/2020 - "The injections were randomly selected among five doses of gadopiclenol (0.025, 0.05, 0.075, 0.1, and 0.2 mmol/kg) and three reference GBCAs (gadoterate meglumine, gadobutrol, and gadobenate dimeglumine) at 0.1 mmol/kg. MRI tumor enhancement was assessed on T1-weighted images before and up to 30 minutes after injection. "
2.	Neoplasm Metastasis (Metastasis) 11/03/2023 - "In a subset of mice that were imaged 1 week earlier, 2 metastases were detected with gadopiclenol and not with gadobenate. " 11/03/2023 - "Contrast-to-noise ratios of the detected metastases were 2.3 and 3.3 times higher with gadopiclenol at 0.08 mmol/kg and 0.1 mmol/kg, respectively, compared with gadobenate at 0.1 mmol/kg (P < 0.0001). " 11/03/2023 - "After gadopiclenol, approximately twice as many metastases were detected compared with gadobenate, regardless of the dose. " 01/01/2019 - "Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength." 11/03/2023 - "The high-relaxivity macrocyclic gadolinium-based contrast agent gadopiclenol allowed higher diagnostic performance for detecting brain enhancing metastases in terms of contrast-to-noise ratio and number of detected metastases compared with gadobenate, at both equal (0.1 mmol/kg) dose and 20% lower Gd dose (0.08 mmol/kg). "
3.	Body Weight (Weight, Body) 01/01/2022 - "Thus, there is no indication for age-based dose adaptation, and comparable plasma gadopiclenol concentrations are predicted to be achieved with body weight-based dosing in this population. " 01/01/2022 - "In a first study, T1 enhancement at 0.1 mmol/kg body weight (bw) of gadopiclenol or gadobenate dimeglumine was evaluated in a small brain lesions rat model at 2.35 T. " 10/01/2022 - "Materials and Methods In this study conducted between May 2018 and April 2020, 9-week-old healthy Sprague Dawley rats received five injections of either gadopiclenol, gadobutrol, or gadodiamide (2.4 mmol of gadolinium per kilogram of body weight for each), or saline (control animals) over a period of 5 weeks. "
4.	Brain Neoplasms (Brain Tumor) 11/03/2023 - "Detection of Brain Metastases by Contrast-Enhanced MRI: Comparison of Gadopiclenol and Gadobenate in a Mouse Model." 11/03/2023 - "The aim of this study was to evaluate the capacity of gadopiclenol, a high-relaxivity gadolinium-based contrast agent to detect brain metastases in mice as a function of dose (0.08 mmol/kg or 0.1 mmol/kg) compared with gadobenate at 0.1 mmol/kg. Brain metastases were induced by ultrasound-guided intracardiac implantation of 1.105 MDA-MB-231Br cells in the left ventricle of 18 anesthetized Balb/c Nude nu/nu female mice. " 01/01/2020 - "Conclusion Gadopiclenol at 0.05 mmol/kg yielded comparable change in contrast-to-noise ratio and morphologic characterization of brain tumors compared with gadobenate, gadoterate, or gadobutrol at 0.1 mmol/kg. Published under a CC BY 4.0 license. " 01/01/2020 - "Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model."
5.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/2021 - "This 2-center, open-label, phase 1 study included 5 successive cohorts of 8 adult subjects: healthy subjects (cohort 1), subjects with mild (cohort 2), moderate (cohort 3), severe (cohort 4) renal impairment, or ESRD (cohort 5), who received a single intravenous injection of gadopiclenol (0.1 mmol/kg). " 01/01/2021 - "In ESRD subjects, gadopiclenol was effectively removed from the plasma after 1 hemodialysis session, and up to 3 hemodialysis sessions were sufficient to completely clear it. " 01/01/2021 - "In ESRD subjects, gadopiclenol was effectively removed from the plasma (95% to 98%) after the first hemodialysis session. " 01/01/2021 - "The aims of this study were to evaluate the pharmacokinetics (PK) of gadopiclenol, a new macrocyclic gadolinium based-contrast agent, in subjects with impaired renal function, and to assess its dialysability in subjects with end-stage renal disease (ESRD). "

Related Drugs and Biologics

1.	Contrast Media
2.	Gadolinium
3.	gadobutrol
4.	gadobenic acid (gadobenate dimeglumine)
5.	gadodiamide (Omniscan)
6.	gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetate
7.	Dihydrotachysterol (AT 10)
8.	gadoterate meglumine
9.	A-factor (Streptomyces)

Related Therapies and Procedures

1.	Injections
2.	Intravenous Injections
3.	Renal Dialysis (Hemodialysis)